Make Informed Investment Decisions with Affordable Access to Experts
Expert Interview
Evaluating the market potential of the Viaskin Milk patch in treating patients with cow’s milk protein allergy (CMPA)
Ticker(s): DBVT, AIMTName: Dr Melanie Makhija - MD
Institution: Northwestern
- Assistant Professor, Pediatrics at Northwestern; Clinical and research interests focus on food allergy including oral, sublingual and epicutaneous immunotherapy for food, eosinophilic esophagitis, asthma, and primary immunodeficiency.
- Treats approximately 500 patients with peanut allergy & 200 patients with cow’s milk allergy (CMPA).
- Primary and co-investigator on several multi-center national and international food allergy, immunology and asthma clinical trials.
Please describe your clinical practice; roughly how many patients with cow’s milk protein allergy (CMPA) do you currently treat?
What is your current treatment for patients with milk allergy?
Added By: userbfe6b45eWhat are your thoughts on the initial data from MILES trial (Viaskin MILk Efficacy and Safety) for Viaskin Milk?
Added By: userbfe6b45eAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
